Building on this, chitosan-coated nanoparticles delivering the same ephrinA1-PE38/GM-CSF construct showed enhanced dendritic cell activation, tumor eradication, and prolonged survival in glioma models, highlighting their promise for personalized immunotherapy (Li et al., 2015a). This evidence concerns the gene CSF2 and central nervous system cancer.